Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy

BioMarin isn’t going to let a rival’s success over the weekend get in the way of making a bee-line to the FDA with an imperfect, but presentable, gene therapy for hemophilia A.